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1. Introduction
  Tuberculosis (TB) is a chronic infectious disease 
caused by Mycobacterium tuberculosis (M. tuberculosis), 
and occasionally by Mycobacterium bovis (M. bovis) 
and Mycobacterium africanum (M. africanum). It is a 
preventable, treatable and curable disease yet it causes 
more death than any other infectious agents in the world. 
Tuberculosis was for very many decades a global problem. 
Tuberculosis (TB) is a significant problem, infecting nearly 
9 million new patients per year and killing about 2 million 
a year. The primary means with which to affect TB globally 
are to decrease transmission locally, mainly by effective 
identification, diagnosis, and treatment of infectious TB 
patients[1]. Breakthrough in the fight against TB came 
in 1943. There was a remarkable decline of tuberculosis 
disease until the mid 1980’s when an upsurge in cases of 
tuberculosis was observed. This has been attributed to 
increase in high risk, immuno-compromised individuals 
especially those infected with HIV, and the emergence 
of drug resistant strains. Tuberculosis alongside malaria 
and HIV/AIDS are 3 major global public health threats 
and they cause substantial morbidity, mortality, negative 
socioeconomic impact, and human suffering. Despite the 
significant increase in financial support and recent progress 
in addressing these 3 diseases, important obstacles and 
unmet priorities remain. Disease-specific interventions 
Objective: To evaluate the success rate of tuberculosis intervention programme at a specialist 
hospital in Ibadan, Nigeria through a retrospective study as well as carry out physicochemical 
evaluation of anti-tuberculous agents as a way of eliminating drug-related failure. Methods: The 
retrospective study involved the use of quarterly tuberculosis central register at the Government 
Chest Hospital, Ibadan between 1st quarter (2003) to 4th quarter (2009). Relevant data were 
extracted from these register with the aid of data collection forms. The basic physicochemical 
analyses of the drugs given to the patients were also carried out using the International 
Pharmacopoeia methods. Results: All the drugs examined for their physicochemical properties 
passed the International Pharmacopeia recommended tests. A total number of 1 260 patients 
enrolled at the hospital were assessed through case notes. This comprises of 59.4% males of which 
69.23% new cases were also males. There was a significant (P<0.05) patient enrollment across the 
quarters for the seven years. An overall 80.24% cure rate over the 7-period was obtained which is 
less than the WHO target of 85%. Cure rates were better in females than males. Failure treatment 
outcomes such as positive (1.51%), deaths (8.73%), defaulted (3.33%) and transferred out (5.95%) 
were recorded though not statistically significant (P>0.05). Failure rates in all categories were 
higher in males than females (P>0.05). Conclusions: More enlightenment and counseling is still 
required to meet up with the target for TB control.
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have had a considerable impact on improving health 
systems. However, despite considerable investment, weak 
health systems, inadequate human resources, and poor 
laboratory infrastructure continue to be major obstacles 
to expanding health services[2]. Although progress has 
been made to reduce global incidence of drug-susceptible 
tuberculosis, the emergence of multidrug-resistant (MDR) 
and extensively drug-resistant (XDR) tuberculosis during 
the past decade threatens to undermine these advances. 
However, countries are responding far too slowly. Of the 
estimated 440 000 cases of MDR tuberculosis that occurred 
in 2008, only 7% were identified and reported to the WHO. 
Of these, only a fifth of the cases were treated according 
to WHO standards. Although treatment of MDR and XDR 
tuberculosis is possible with currently available diagnostic 
techniques and drugs, the treatment course is substantially 
more costly and laborious than for drug-susceptible 
tuberculosis, with higher rates of treatment failure and 
mortality[3].
  A proven strategy to ensure patients’ adherence to anti-
tuberculosis medication is the use of Directly Observed 
Treatment Short course (DOTS) therapy. In DOTS, a health 
care provider observes the patient or other responsible person 
as the patient ingest the anti-tuberculosis medication. The 
DOTS provides the opportunity for patient education and 
also enables early detection of adverse effects[4]. Other key 
components of DOTS as specified by WHO are: political 
commitment with increased and sustained financing, 
legislation, planning, human resources, management, 
training; case detection through quality-assured 
bacteriology, strengthening TB laboratories, drug resistance 
surveillance; standardized treatment with supervision and 
patient support TB treatment and programme management 
guidelines; an effective drug supply and management system 
through availability of TB drugs, TB drug management 
as well as monitoring and evaluation system and impact 
measurement[4].
   Tuberculosis has emerged as the single leading cause of 
death from any single infectious agent[5]. Despite being the 
world's leading bacterial cause of death, 95% of infection 
is believed to exist in an asymptomatic ’latent’ form that is 
defined not by the identification of bacteria, but by the host 
immune response in the form of reactivity to tuberculosis 
proteins in the tuberculin skin test. It seems likely that 
clinically defined latent tuberculosis actually represents 
a spectrum that runs from elimination of live bacilli to 
subclinical disease[6]. In addition, the recent figures put 
the DOTS detection rate of new sputum smear positive to be 
below 20% while the treatment success of new sputum smear 
positive still falls below the WHO target of 85%[7]. Thus, there 
is need to carry out field study on DOTS in order to evaluate 
its treatment success rate.
  In Ibadan, Southwestern Nigeria, a government-owned 
secondary health care hospital is charged with the 
responsibility of ensuring adequate provision of the DOTS 
programme as a strategy towards combating the spread of 
TB in the populace. The main objective of this study was 
centered at improving the overall pharmaceutical care 
received by tuberculosis patients at the Government Chest 
hospital, Jericho, Ibadan, which is a specialist hospital. The 
specific objectives were aimed at evaluating the impact of 
DOTS intervention on tuberculosis patients in achieving 
total control and to provide a platform for the pursuit of high 
quality DOTS expansion and enhancement. Physicochemical 
evaluations of the drugs utilized at the centre were also 
carried out in order to eliminate drug quality-related 
failures. 
2. Materials and methods
2.1. Study design
  The nature of the study of evaluation of Directly Observed 
Treatment short courses (DOTS) was descriptive and this 
entailed retrospective study of case files of positive TB 
cases. The retrospective study involved the use of quarterly 
tuberculosis central register at the Government Chest 
Hospital, Ibadan between 1st quarter (2003) to 4th quarter 
(2009). Relevant data were extracted from these register with 
the aid of data collection forms. 
  The basic physical and chemical analyses of the drugs 
given to the patients were also carried out in order to 
ascertain the quality of the drugs and eliminate drug-quality 
related cause of failure.
2.2. Ethical approval
  The ethical approval to examine patients’ case files 
was given by the Director of Medical Services, Hospital 
Management Board, Ibadan, Oyo State. The names of the 
patients were not adopted for the study.
2.3. Parameters assessed
  The parameters that were measured from the quarterly 
tuberculosis register are the following; the number of patient 
that attended the clinic, the category of patient that attended 
the clinic (which could be; new patient: never previously 
treated for as much as 1 month, relapse: previously treated 
and declared cured returns smear positive, failure: positive 
smear 5 or more months after starting treatment put on 
retirement, RAD: Return after default and transfer in: 
registered and started treatment in another district), the 
number of female patients and male patients that attended 
the clinic and the treatment outcomes for each patient 
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(which could be; cured: negative smear at last month of 
treatment and on one previous occasion, positive i. e. failure: 
positive smear at 5 months or later during treatment, died: 
died from any cause during treatment, defaulted: failed to 
collect medications for more than 2 month after date last 
seen, transferred out: sent to another district for continuation 
of treatment).
2.4. Estimation of cure rates
  The cure rate for each quarter was estimated by the number 
of negative smears as a fraction of the total patients recorded 
for the quarter from the expression:
伊100
The percentage of patient cured for the quarter
Total mumber of negative smear (cured)
Total number of patients for the quarter
=
Summary tables were prepared for the twenty eight quarters 
taking into consideration the above parameters and 
comparing their results.
2.5. Physicochemical analyses of anti-tuberculous agents
  Basic chemical and physical tests were carried out on the 
anti-tuberculosis drugs given to patients as specified in the 
International Pharmacopoeia[8]. This was done in order to 
ensure that treatment failures were not due to poor quality 
drugs. The drugs analyzed include; rifampicin capsule, 
pyrazinamide tablet, ethambutol hydrochloride tablet, 
isoniazid tablet and streptomycin sulfate for injection.
2.5.1. Identification tests for rifampicin
  A 0.392 5 g quantity of powdered tablet equivalent to 50 mg
of rifampicin was dissolved in methanol and 1 mL of the 
solution was diluted to 50 mL with phosphate buffer, pH 
7.4. The absorption spectrum of the resulting solution, when 
observed between 220 nm and 500 nm, would exhibit 4 
maxima at about 237 nm, 254 nm, 334 nm and 475 nm; the 
ratio of the absorbance of a 1 cm layer at the maximum at 
about 334 nm to that at the maximum at about 475 nm was 
assessed.
2.5.2. Test for pyrazinamide
  For test A, 0.157g of the powdered tablets equivalent to 
0.05 g of pyrazinamide was dissolved in 50 mL of water and 
filtered. 1 mL of the filtrate was diluted to 100 mL with water. 
The absorption spectrum of this solution, when observed 
between 230 nm and 350 nm, would exhibit two maxima. The 
ratio of the absorbance of a 1 cm layer at 268 nm to that at 
310 nm was determined.
  For test B, 0.189 g of the powdered tablets equivalent to 
0.06 g of pyrazinamide, 5 mL of sodium hydroxide (80 g/L) 
was added and heated on water bath; vapours were evolved. 
The colour of moistened pH-indicator paper inserted into 
the vapours was noted. 
2.5.3. Test for ethambutol hydrochloride
  Ten mL of methanol was added to 0.165 g of powdered 
tablet equivalent 0.1 g of ethambutol and shaken. The 
extract was filtered and evaporated to dryness. The residue 
was the acidified with nitric acid (130 g/L) and silver nitrate 
(40 g/L) was added. The result was noted.
2.5.4. Test for isoniazid
  Twenty mL of water was added to 0.439 g of the powdered 
tablet equivalent to about 0.1 g of isoniazid, it was shaken 
and filtered. A mixture composed of 1.0 mL of silver nitrate 
(40 g/L) and 1.0 mL ammonia (100 g/L) was added. The results 
were noted. 
2.5.5. Test for streptomycin sulfate 
  For test A, 0.136 g streptomycin powder for injection 
equivalent to 0.1 g of streptomycin sulfate was dissolved 
in 2 mL of water, and 1 mL of 1-naphthol was added and
2 mL of a mixture of equal volumes of sodium hypochlorite 
(40 g/L) and water was also added. The colour produced was 
recorded.
  For test B, 0.068 g of streptomycin powder for injection 
equivalent to 50 mg of streptomycin sulfate was dissolved in 
water. Barium chloride (50 g/L) was added. The precipitate 
formed was noted, and its solubility in hydrochloric acid 
(250 g/L) was observed. 
  For test C, the clarity and colour of solution was observed 
using 3.4 g of streptomycin powder for injections which is 
equivalent to 2.5 g of streptomycin sulfate. The sample was 
dissolved in 10 mL of carbon-dioxide-free water. The clarity 
and colour were noted. 
  For test D, the pH value of the solution prepared above for 
the test of clarity and colour was taken.  
2.6. Statistical analysis
  The data collected for the retrospective study were 
analyzed using percentages as the descriptive statistics. The 
Levene’s test for equality of variances was done for treatment 
outcomes within each quarter. ANOVA was adopted to study 
the observed responses for all the quarters with Duncan’s 
multiple comparison test for significant differences between 
each year, P<0.05 were taken as significant.   
 
3. Results
  All the drugs sourced which are currently being used for 
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the directly observed treatment short course of tuberculosis 
passed all the tests specified in the International 
Pharmacopoeia. This has eliminated any reason for failure 
of therapy as being due to poor-quality drugs. At least, the 
drugs contain the stated medicaments. The assays of the 
drugs were not carried out due to the inability to source 
enough drugs from the secondary health care centre. The 
samples obtained were just used for the identification test. 
The spectra of rifampicin and pyrazinamide are presented in 
Figures 1 and 2, respectively.
  The overall summary of the treatment courses for the 
seven-year retrospective study is presented in Table 1 
while Table 2 presents a typical yearly report sheet with 
2008 used as a model in the table. Table 3 presents the 
overall percentage summary for the total patients in each 
three categories (number of patients, category of patients 
and results of treatments) studied. From Tables 1 & 3, the 
total number of patients recruited into the treatment for the 
period was 1 260 of which 59.4% were males and 40.6% were 
females. Thus a higher number of male subjects reported for 
the treatment during the period. The tables also show the 
category of the patients as new, relapse, failure, return after 
default, transferred and others who do not fall into any of the 
aforementioned category. For the 28 quarters studied, the % 
new case relative to the total of patients was 84.6% of which 
males constitute 69.23% and females 30.77%. Thus a higher 
number of males were registered as new cases. Studying the 
effects of gender, there was statistical significant difference 
in the total number of patients registered and among those 
that transferred in (P<0.05). This was anticipated since there 
was a wide gap between the numbers of males compared 
to females that enrolled for treatment. Among the males, 
statistical significant difference exist in “transferred in” 
(P=0.001) and “others” (P=0.036) cases. For females there 
Table 1 
Overall quarterly summary of patient enrollment and treatment outcomes for 2003-2009.
Parameters
Quarter 1 Quarter 2 Quarter 3 Quarter 4
Total Male Female Total Male Female Total Male Female Total Male Female
Number of patients 325 197 128 307 185 122 297 168 129 331 199 132
Category of patients
New 271 159 112 256 153 103 256 144 112 283 170 113
Relapse     7     6     1     7     5     2     8     7     1   14     8     6
Failure     2     1     1     4     4     0     3     1     2     5     5     0
Return after default (RAD)   11     7     4     2     2     0     0     0     0     3     2     1
Transferred in   21   13     8   21   16     5   19   10     9   20   13     7
Others   13   11     2   15     9     6   11     6     5     9     4     5
Results of treatment
Negative (Cured) 269 162 107 232 133   99 243 137 106 267 155 112
Positive (Failure)     2     1     1     8     6     2     4     0     4     5     5     0  
Died   24   16     8   33   22   11   30   19   11   23   14     9
De-faulted   11     9     2   14   13     1     9     5     4     8     7     1
Transferred out   19     9   10   20   11     9     9     5     4   27   17   10
Percentage cure rate (%) 82.77 82.23 83.60 75.57 71.89 81.15 81.82 81.55 82.17 80.66 77.89 84.85
Table 2
Typical yearly report for patients’ inventory and treatment outcomes (Year 2008).
Parameters
 Quarter 1  Quarter 2 Quarter 3 Quarter 4
Total Male Female Total Male Female Total Male Female Total Male Female
Number  of patients 53 29 24 55 33 22 57 38 19 56 38 18
Category of patients
New 48 26 27 43 27 16 53 35 18 46 32 14
Relapse Nil Nil Nil   4   3   1   2   1   1   3   2   1
Failure   1 Nil   1   1   1 Nil Nil Nil Nil   1   1 Nil
Return after default (RAD) Nil Nil Nil Nil Nil Nil Nil Nil Nil   2   1   1
Transferred  in   2   2 Nil   1   1 Nil   2   2 Nil   2   1   1
Others   2   1   1   6   1   5 Nil Nil Nil   2   1   1
Results of treatment
Negative (Cured) 44 24 20 38 22 16 53 35 18 50 34 16
Positive (Failure) Nil Nil Nil   2   2 Nil Nil Nil Nil Nil Nil Nil
Died   3   2   1   6   2   4   3   2   1   3   2   1
De-faulted   1   1 -   3   3 Nil   1   1 Nil   3   2   1
Transferred out   5   2   3   6   4   2 Nil Nil Nil Nil NIL Nil
Percentage cure rate (%) 91.7 82.8 83.3 69.1 66.7 72.7 93.0 92.0 94.7 89.3 89.5 88.9
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was no significant difference among the number of patients 
(P>0.05). The 4th quarter 2006 witnessed the lowest number 
of new cases and 1st quarter 2006 witnessed a corresponding 
highest new cases. Among the category of patients were 
those returning after failure, defaulted and “transferred 
in” which represent 2.86%, 1.12%, 11.27% and 6.93%, 
respectively. The cases categorized as “new” show statistical 
significant difference across the quarters for the seven-
year period (P<0.05) while Duncan multiple comparison test 
shows that 2007 (the lowest) and 2006 (highest) contributed to 
the significant difference. Statistical significant differences 
were also observed among transferred in, RAD and others 
(P<0.05). For RAD, 2003 and 2007 (lowest) and 2009 (highest) 
contributed to the observed pattern.  
  The treatment outcomes were categorized as cured 
(showing negative sputum smear test), positive (showing 
positive smear test), died, defaulted and transferred out. 
Cure rates were generally better in female than male 
patients when weighted as a ratio of the total number of 
patients by gender. However, on the whole as a ratio of the 
total patients cure rates were higher in males than female 
since a higher number of males registered (Table 3, P>0.05). 
The overall average cure rate of 82.24% was recorded for 
the seven-year period. The cure rate for male of the total 
number of male patients was 78.37% while that of female 
relative to the total female was 82.97%. There thus appears to 
be a better cure rate among female than male justifying that 
the female comply better with treatment courses than their 
male counterparts. The cure rate among each of the quarters 
for the seven-year period is presented in Figure 3a while 
Figure 3b shows the positive failure rate for the treatment 
period. There was no statistical significant difference in all 
treatment outcomes for the seven-year period (P>0.05). Also 
there was no significant difference among each group of 
males and females in all treatment outcomes (P>0.05).
  The failure rates for the DOTS programme in the centre 
studied for the seven-year period is presented in Table 4.
The highest failure rate; representing positive smear cases 
only excluding deaths, defaulters and transferred out, 
occurred at the 2nd of 2009 and got carried over to 3rd 
quarter. However, failure rate came to a minimum by 4th 
quarter. Years 2006 and 2007 as well as 2008 witnessed the 
lowest failure rates. In particular, there was no record of 
positive smear cases amongst patients in 1st to 3rd quarter 
of 2006 and 2007.
  The % death recorded from the TB cases for the 2003-
2009 period in the centre studied is presented in Table 5. 
The highest % deaths were recorded in 2nd quarter (for both 
males and females). Although when related by each quarter 
and year, 1st quarter 2003 and 4th quarter 2003 had the 
highest and lowest deaths respectively.  
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Figure 1. Absorption spectrum of rifampicin.
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Figure 2. Absorption spectrum of pyrazinamide.
Table 3
Overall Summary for the treatment courses for the seven-year 
period.
Parameters
Overall percentages (%)
Total Male Female
Number of patients                 100.00 59.40 40.60
Category of patients New   84.60 89.23 30.33
Relapse     2.86 72.22 27.78
Failure     1.12 78.57 21.43
Return after default     1.27 68.75 31.25
Transferred  in     6.43 64.20 35.80
Others     3.81 62.50 37.50
Results of treatment Negative (Cured)   80.24 58.06 41.94
Positive (Failure)     1.51 63.16 36.84
Died     8.73 64.55 35.45
De-faulted     3.33 80.95 19.05
Transferred out     5.95 56.00 44.00
Percentage cure rate   80.24 78.37* 82.97*
 *Weighted as a total for each gender category.
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Figure 3. Results of negative (a) and positive (b) cure rates for the 
years studied. 
Table 4
Percentage failure rates for TB treatment at the DOTs centrea.
Year
Failure rates (%)
Quarter 1 Quarter 2 Quarter 3 Quarter 4
2003 2.38 0.00 6.90 0.00
2004 2.38 2.44 0.00 3.92
2005 0.00 1.82 0.00 2.08
2006 0.00 0.00 0.00 2.56
2007 0.00 0.00 0.00 2.13
2008 0.00 3.64 0.00 0.00
2009 0.00 8.89 4.45 0.00
a
Percentage failure rates refer to only positive cases following 
treatment (deaths, defaulters and transferred out are excluded).
Table 5
% Death recorded from TB patients (2003-2009). 
% Death Quarter 1 Quarter 2 Quarter 3 Quarter 4
Overalla   7.38 10.75 10.10   6.95
Malea 66.67 66.67 63.33 60.87
Femalea 33.33 33.33 36.67 39.13
Maleb   8.12 11.89 11.31   7.04
Femaleb   6.25   9.02   8.53   6.82
a
Calculated as a function of total deaths recorded and bas a function of 
total patients in each category.
4. Discussion
  In this study, the evaluation of DOTS was done 
retrospectively using the retained quarterly tuberculosis 
control register at the Government Chest Hospital, Ibadan 
while basic chemical and physical tests were carried on 
the anti-tuberculosis drugs given to the patients. The basic 
tests carried out reveals that all the drugs being used for the 
treatment courses contain the active ingredients. 
  In addition to the physicochemical evaluation of the anti-
TB drugs as a way of eliminating drug-related factors in 
DOTS therapy, a retrospective assessment of the case notes 
of patients attended to for four quarters over a 7-seven 
period was conducted. To the best of our knowledge this 
is the first comprehensive retrospective evaluation of the 
treatment strategy at this specialist treatment centre in 
Ibadan, Nigeria. Varying results were obtained with respect 
to the several treatment outcomes envisaged from any DOTS 
programme. The results should help in improving the care 
afforded the patients at this secondary health care facility. 
  From an examination of this study, there appears to 
be substantial new cases of TB recorded over the study 
period. The implication of this is that the battle against 
this disease is long from being won. It will actually require 
more efforts and better socio-economic considerations to 
improve the situation. The discovery of other conditions, 
primarily HIV/AIDS, leading to complications in cases of 
immuno-compromised patients appears to be increasing 
the cases of TB. Although, some other underlining factors 
were not considered in this study, several other factors 
previously identified may as well be responsible for the 
incidence of new cases observed in this study. Salami et 
al[9] identified predisposing factors to TB as consisting of 
low socioeconomic status, overcrowding and poor living 
conditions. In all, new cases constitute over 80% of patients 
that reported for treatment at this centre over the 7-year 
period. This appears alarming on one hand, but on the 
other hand it appears more people are forsaking the stigma 
associated with the condition to report at this health provider 
centre.
  Male patients contributed to two-thirds of the new cases 
of TB observed. This is consonance with the report of 
Salami et al[9] in Ilorin, a north-central state where 55% 
of the cases considered over a 4-year period were males. 
Males are known to be at an increased risk of contracting 
this disease due to several risk factors, occupational 
hazards, carefree attitudes and some other lifestyle choices 
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that can compromise immunity. The percentage of new 
cases recorded across the various 28 quarters studied 
were statistically significantly different from one another 
(P=0.013). This is clearly evident from the number of new 
cases observed in Table 1. Duncan’s multiple comparison 
tests revealed that 2007 has the lowest report of new cases 
and 2006 has the highest incidences of new cases being 
enrolled into the DOTS programme. 
  Among the category of patients studied were those that fall 
under relapse, failure, return after default and transferred 
in. Although the percentage of relapse cases are few, 
contributing  2.86% of the total patients studied, their 
occurrence suggest lack of compliance to medication or 
the attitude of missing one clinic visit or another. Patient 
compliance has been identified as a critical problem early 
in the provision of treatment courses for TB control[10]. Once 
again, the males are responsible for greater than two-thirds 
of the relapse cases. Those returning after failure and default 
are in the range of 1.12% and 1.27%, respectively with males 
being responsible for a greater percentage of this category 
of patients. The percentage of patients that transferred in to 
the services provided at the Chest clinic studied constitutes 
6.43% of which males are 64.2%. That people are transferring 
in to the DOTS programme suggests awareness of existence 
of a treatment centre in their new location which portends 
a good trend for the control of TB. In addition, recent 
enlightenment on radio and local television stations about 
the need for people to report to these centres may have 
had a positive influence on the number of “transferred in” 
observed. This initiative sponsored by the Federal Ministry 
of Health of Nigeria in partnership with global fund is highly 
commendable. 
  Common classification of treatment outcomes from 
TB cases are; cured (in which a negative smear test is 
produced), positive (i.e. failure), died, defaulted and 
transferred out. In Nigeria, the treatment success rate was 
79% in 2002, this increased to 85% in 2003. However, default 
remain as high as 11% in the 2-year period while death 
was up to 6.7%[11]. The recommended target cure rate by 
WHO is 85%. From the result of our retrospective study, 
the overall cure rate observed over the 7-year period from 
this TB primary care-giving centre is 80.24%. This is a far 
cry from the targeted success rate expected from the DOTS 
programme; hence more efforts are still required to meet 
up with this target. When each gender category is weighed 
on each other, females (82.97%) had better cure rates than 
males (78.37%). The reason adducible for this may be that 
females show better compliance to medications, may be 
more regular at hospital visits and females are known to 
exhibit less care-free attitudes to health conditions than 
males. Males have been identified in several studies to be 
at an increased risk of a poor treatment outcome compared 
to females[12,13]. Other poor treatment outcomes identified in 
this retrospective study include failure (1.51%), died (8.73%), 
defaulted (3.33%) and transferred out (5.95%). Third quarter 
of 2009 had the highest positive (failure) rate while quarter 
4 in most of the years recorded substantial failure rates. It 
appears that most patients seem to be fed up with treatment 
courses towards the end of the year. This is a factor that 
care givers must look into and adequate counsel given as 
such failure rates must not only be perceived as patient 
failures but also failure of the care-givers themselves[14]. 
However, TB control in large urban settings poses a unique 
challenge for many national TB programmes including those 
in low-income countries. This is attributed to a number of 
factors including social, operational, economic, managerial 
constraints and poverty[15-19]. In a longitudinal study 
involving a cohort of sputum smear-positive patients with 
pulmonary TB in Ibadan in 2008, Fatiregun et al[20] reported 
the cure rates varying significantly among treatment centres 
in Ibadan with that in Teaching Hospital and the present 
centre considered in our study having the highest cure rates. 
The default rates were as high as 6.6% while a similar study 
in Ile-Ife, another southwestern Nigerian city, over a ten-
year period[21] gave default rate as high as 27%. Many factors 
have been identified for defaulting in any DOTS programme. 
Some obvious differences between defaulters and those who 
completed the treatment have been identified. Defaulters 
were shown to have the highest rates of those who are not 
satisfied with the treatment offered. Some were known to 
stop treatment prematurely because of side effects from 
medications or the perception that they were cured[22]. 
This is where the practical aspect of pharmaceutical care 
will play a major role in educating patients at the outset of 
therapy that side effects are bound to occur and completion 
of treatment is the only way to guarding against recurrence 
and treatment failure.
  A not too satisfactory percentage of the patients died during 
the course of the 7-year retrospective study conducted at 
this specialist hospital. The deaths recorded are presented 
in Table 5. Highest number of deaths was recorded in 
third quarter relative to the other three quarters across the 
7-year period. Although there was no statistical significant 
difference (P>0.05) in the deaths recorded across the 
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quarters, years and across gender line, the rates still appears 
too high. Once again, the male patients are responsible for 
most of the deaths reported. This leaves more to be desired 
and in essence more advocacy must be done to enlighten the 
populace that deaths are still recorded from TB cases even 
in the 21st century.
  In conclusion, this retrospective study has established 
that the target cure rate as stipulated by the WHO has not 
been accomplished in this health care centre, although 
quite close to it. More success rate will be observed as 
enlightenment is increased and better counseling services 
are provided by care-givers. The current awareness of the 
disease in public broadcasting stations across the length and 
breadth of Nigeria is commendable and must be sustained to 
accomplish the targeted result. 
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